Isofol Medical

0.72 SEK

-0.96 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.96 %
+1.27 %
+22.97 %
-1.23 %
+4.12 %
-31.72 %
+34.54 %
-91.72 %
-94.66 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.

Read more
Market cap
230.75M SEK
Turnover
181.67K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.8
2026

Interim report Q2'26

12.11
2026

Interim report Q3'26

12.2
2027

Annual report '26

ShowingAll content types
Third party research

Isofol Medical: Taking action on recruitment - ABG

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...

Isofol Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Isofol Medical

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.